{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    7,
    8,
    9
  ],
  "modelUsed": "gemini-3-flash-preview",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Safety and Tolerability Objective",
        "text": "To assess the local and systemic safety and tolerability of ABBV-951 delivered as a CSCI for 24 hours daily for up to 52 weeks.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1",
          "ep_2",
          "ep_3",
          "ep_4",
          "ep_5",
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Efficacy Objective",
        "text": "To assess the efficacy of ABBV-951 as measured by patient-reported and rater-measured efficacy endpoints.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_7",
          "ep_8",
          "ep_9",
          "ep_10",
          "ep_11"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Exploratory Objective",
        "text": "To evaluate PD symptoms via wearable device and biomarker research.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_12",
          "ep_13"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Adverse Events",
        "text": "Percentage of subjects with adverse events (AEs) and serious adverse events (SAEs) during the study",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_2",
        "name": "Adverse Events of Special Interest",
        "text": "Percentage of subjects with AEs of special interest (AESIs) during the study",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_3",
        "name": "Infusion Site Evaluation Scale",
        "text": "Percentage of subjects with numeric grade equal to or higher than 5 and percentage of subjects with letter grade equal to or higher than D on the Infusion Site Evaluation Scale at any time during the study",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Tolerability"
      },
      {
        "id": "ep_4",
        "name": "Clinical Laboratory Test Data",
        "text": "Change in clinical laboratory test data from Baseline to end of study",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_5",
        "name": "Vital Sign Measurements",
        "text": "Change in vital sign measurements from Baseline to end of study",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_6",
        "name": "Electrocardiograms (ECGs)",
        "text": "Change in electrocardiograms (ECGs) from Baseline to end of study",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_7",
        "name": "PD Diary Off and On Times",
        "text": "Average normalized daily \"Off\" time and \"On\" times as assessed by the PD Diary",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "MDS-UPDRS Parts I-IV",
        "text": "PD symptoms as assessed by the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I-IV (or the UPDRS Parts I-V in countries where a validated translation of the MDS-UPDRS is not available)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_9",
        "name": "PDSS-2",
        "text": "Sleep symptoms as assessed by the PD Sleep Scale-2 (PDSS-2)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_10",
        "name": "PDQ-39",
        "text": "Quality of life as assessed by the PD Questionnaire-39 items (PDQ-39)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_11",
        "name": "EQ-5D-5L",
        "text": "Health-related quality of life as assessed by the EuroQol 5-dimensions questionnaire (EQ-5D-5L)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_12",
        "name": "PKG Wearable Device",
        "text": "PD symptoms (including tremor, bradykinesia, dyskinesia, daytime somnolence, and indication of propensity for impulsive behaviors) as assessed by the Parkinson's KinetiGraph™/Personal KinetiGraph™ (PKG) wearable device (as allowed by local regulations) from Baseline to the Week 26 Visit.",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_13",
        "name": "Biomarker Research Endpoints",
        "text": "Optional samples will be collected during the study to evaluate known and/or novel biomarkers related to PD, related conditions, ABBV-951, or drugs of a similar class.",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Safety Estimand - Adverse Events",
        "populationSummary": "Adult patients with Parkinson's Disease whose motor symptoms are inadequately controlled by current therapy (Safety Population) Summary measure: Percentage (Proportion).",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Subject discontinues ABBV-951 infusion prior to Week 52",
            "strategy": "While on Treatment",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Death",
            "text": "Death of the subject during the 52-week study period",
            "strategy": "While on Treatment",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "ABBV-951 continuous subcutaneous infusion (CSCI) for 24 hours daily",
        "analysisPopulation": "Adult patients with Parkinson's Disease whose motor symptoms are inadequately controlled by current therapy (Safety Population)",
        "variableOfInterest": "Percentage of subjects with adverse events (AEs) and serious adverse events (SAEs) during the study",
        "summaryMeasure": "Percentage (Proportion)"
      },
      {
        "id": "est_2",
        "name": "Primary Safety Estimand - Infusion Site Tolerability",
        "populationSummary": "Adult patients with Parkinson's Disease whose motor symptoms are inadequately controlled by current therapy (Safety Population) Summary measure: Percentage (Proportion).",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_3",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Subject discontinues ABBV-951 infusion prior to Week 52",
            "strategy": "While on Treatment",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "ABBV-951 continuous subcutaneous infusion (CSCI) for 24 hours daily",
        "analysisPopulation": "Adult patients with Parkinson's Disease whose motor symptoms are inadequately controlled by current therapy (Safety Population)",
        "variableOfInterest": "Percentage of subjects with numeric grade ≥ 5 or letter grade ≥ D on the Infusion Site Evaluation Scale",
        "summaryMeasure": "Percentage (Proportion)"
      },
      {
        "id": "est_3",
        "name": "Secondary Efficacy Estimand - Off Time",
        "populationSummary": "Adult patients with Parkinson's Disease whose motor symptoms are inadequately controlled by current therapy (ITT Population) Summary measure: Mean change from baseline.",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_7",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Subject discontinues ABBV-951 infusion prior to Week 52",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_3",
            "name": "Use of rescue medication",
            "text": "Use of prohibited or rescue PD medications during the study",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "ABBV-951 continuous subcutaneous infusion (CSCI) for 24 hours daily",
        "analysisPopulation": "Adult patients with Parkinson's Disease whose motor symptoms are inadequately controlled by current therapy (ITT Population)",
        "variableOfInterest": "Change from Baseline to end of study in average normalized daily 'Off' time as assessed by the PD Diary",
        "summaryMeasure": "Mean change from baseline"
      }
    ],
    "summary": {
      "primaryObjectives": 1,
      "secondaryObjectives": 1,
      "exploratoryObjectives": 1,
      "totalEndpoints": 13,
      "totalEstimands": 3
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Safety and Tolerability Objective",
        "text": "To assess the local and systemic safety and tolerability of ABBV-951 delivered as a CSCI for 24 hours daily for up to 52 weeks.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1",
          "ep_2",
          "ep_3",
          "ep_4",
          "ep_5",
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Efficacy Objective",
        "text": "To assess the efficacy of ABBV-951 as measured by patient-reported and rater-measured efficacy endpoints.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_7",
          "ep_8",
          "ep_9",
          "ep_10",
          "ep_11"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Exploratory Objective",
        "text": "To evaluate PD symptoms via wearable device and biomarker research.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_12",
          "ep_13"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Adverse Events",
        "text": "Percentage of subjects with adverse events (AEs) and serious adverse events (SAEs) during the study",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_2",
        "name": "Adverse Events of Special Interest",
        "text": "Percentage of subjects with AEs of special interest (AESIs) during the study",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_3",
        "name": "Infusion Site Evaluation Scale",
        "text": "Percentage of subjects with numeric grade equal to or higher than 5 and percentage of subjects with letter grade equal to or higher than D on the Infusion Site Evaluation Scale at any time during the study",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Tolerability"
      },
      {
        "id": "ep_4",
        "name": "Clinical Laboratory Test Data",
        "text": "Change in clinical laboratory test data from Baseline to end of study",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_5",
        "name": "Vital Sign Measurements",
        "text": "Change in vital sign measurements from Baseline to end of study",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_6",
        "name": "Electrocardiograms (ECGs)",
        "text": "Change in electrocardiograms (ECGs) from Baseline to end of study",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_7",
        "name": "PD Diary Off and On Times",
        "text": "Average normalized daily \"Off\" time and \"On\" times as assessed by the PD Diary",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "MDS-UPDRS Parts I-IV",
        "text": "PD symptoms as assessed by the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I-IV (or the UPDRS Parts I-V in countries where a validated translation of the MDS-UPDRS is not available)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_9",
        "name": "PDSS-2",
        "text": "Sleep symptoms as assessed by the PD Sleep Scale-2 (PDSS-2)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_10",
        "name": "PDQ-39",
        "text": "Quality of life as assessed by the PD Questionnaire-39 items (PDQ-39)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_11",
        "name": "EQ-5D-5L",
        "text": "Health-related quality of life as assessed by the EuroQol 5-dimensions questionnaire (EQ-5D-5L)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_12",
        "name": "PKG Wearable Device",
        "text": "PD symptoms (including tremor, bradykinesia, dyskinesia, daytime somnolence, and indication of propensity for impulsive behaviors) as assessed by the Parkinson's KinetiGraph™/Personal KinetiGraph™ (PKG) wearable device (as allowed by local regulations) from Baseline to the Week 26 Visit.",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_13",
        "name": "Biomarker Research Endpoints",
        "text": "Optional samples will be collected during the study to evaluate known and/or novel biomarkers related to PD, related conditions, ABBV-951, or drugs of a similar class.",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Safety Estimand - Adverse Events",
        "populationSummary": "Adult patients with Parkinson's Disease whose motor symptoms are inadequately controlled by current therapy (Safety Population) Summary measure: Percentage (Proportion).",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Subject discontinues ABBV-951 infusion prior to Week 52",
            "strategy": "While on Treatment",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Death",
            "text": "Death of the subject during the 52-week study period",
            "strategy": "While on Treatment",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "ABBV-951 continuous subcutaneous infusion (CSCI) for 24 hours daily",
        "analysisPopulation": "Adult patients with Parkinson's Disease whose motor symptoms are inadequately controlled by current therapy (Safety Population)",
        "variableOfInterest": "Percentage of subjects with adverse events (AEs) and serious adverse events (SAEs) during the study",
        "summaryMeasure": "Percentage (Proportion)"
      },
      {
        "id": "est_2",
        "name": "Primary Safety Estimand - Infusion Site Tolerability",
        "populationSummary": "Adult patients with Parkinson's Disease whose motor symptoms are inadequately controlled by current therapy (Safety Population) Summary measure: Percentage (Proportion).",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_3",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Subject discontinues ABBV-951 infusion prior to Week 52",
            "strategy": "While on Treatment",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "ABBV-951 continuous subcutaneous infusion (CSCI) for 24 hours daily",
        "analysisPopulation": "Adult patients with Parkinson's Disease whose motor symptoms are inadequately controlled by current therapy (Safety Population)",
        "variableOfInterest": "Percentage of subjects with numeric grade ≥ 5 or letter grade ≥ D on the Infusion Site Evaluation Scale",
        "summaryMeasure": "Percentage (Proportion)"
      },
      {
        "id": "est_3",
        "name": "Secondary Efficacy Estimand - Off Time",
        "populationSummary": "Adult patients with Parkinson's Disease whose motor symptoms are inadequately controlled by current therapy (ITT Population) Summary measure: Mean change from baseline.",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_7",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Subject discontinues ABBV-951 infusion prior to Week 52",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_3",
            "name": "Use of rescue medication",
            "text": "Use of prohibited or rescue PD medications during the study",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "ABBV-951 continuous subcutaneous infusion (CSCI) for 24 hours daily",
        "analysisPopulation": "Adult patients with Parkinson's Disease whose motor symptoms are inadequately controlled by current therapy (ITT Population)",
        "variableOfInterest": "Change from Baseline to end of study in average normalized daily 'Off' time as assessed by the PD Diary",
        "summaryMeasure": "Mean change from baseline"
      }
    ]
  }
}